Melorheostosis: genes and variants
Explore variant evidence for Melorheostosis across 1 analyzed protein (MAP2K1). Linked ClinVar records include 2 pathogenic or likely pathogenic variants, 10 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Melorheostosis
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
2 ClinVar pathogenic / likely pathogenic and 12 uncertain variants in MAP2K1 have source records linked to Melorheostosis. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Melorheostosis
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MAP2K1 K57N | 57 | Pathogenic / likely pathogenic (★★) | |
| MAP2K1 K57E | 57 | Pathogenic / likely pathogenic |
Same protein, different disease
- RASopathy also has ClinVar records linked to MAP2K1 variants; they fall mostly in different places as the Melorheostosis variants (14 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall mostly in different places as the Melorheostosis variants (14 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall mostly in different places as the Melorheostosis variants (6 pathogenic / likely pathogenic).
Diseases related to Melorheostosis
- Hypertrophic cardiomyopathy, also linked to MAP2K1
- RASopathy, also linked to MAP2K1
- Noonan syndrome, also linked to MAP2K1
- Noonan syndrome and Noonan-related syndrome, also linked to MAP2K1
- Neurofibromatosis, also linked to MAP2K1
- Cardiofaciocutaneous syndrome, also linked to MAP2K1
- Cardio-facio-cutaneous syndrome, also linked to MAP2K1
- Non-small cell lung carcinoma, also linked to MAP2K1
- Costello syndrome, also linked to MAP2K1
- Vascular malformation, also linked to MAP2K1
- Male infertility with azoospermia or oligozoospermia due to single gene mutation, also linked to MAP2K1
- Noonan syndrome with multiple lentigines, also linked to MAP2K1
Frequently asked questions
Which genes have records linked to Melorheostosis?
This view contains 1 analyzed proteins: MAP2K1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 2 pathogenic or likely pathogenic variants, 10 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 19 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center